Faculty
Jordan McPherson, PharmD, MS, BCOP
Oncology Clinical Pharmacist
Huntsman Cancer Institute
Adjunct Assistant Professor
University of Utah College of Pharmacy
Salt Lake City, Utah
Jordan McPherson, Pharm.D., M.S., BCOP is Oncology Clinical Pharmacist in the ambulatory solid tumor clinics at the Huntsman Cancer Institute, an NCI designated cancer hospital, at the University of Utah Health and Adjunct Assistant Professor at the University of Utah College of Pharmacy in Salt Lake City, Utah. Dr. McPherson specializes in the treatment of skin cancer using immunotherapy and other targeted therapies. He serves as a Panelist on the NCCN Guidelines for Management of Immune Checkpoint Inhibitor-Related Toxicities, and is Past President of the Utah Society of Health-System Pharmacists. Dr. McPherson’s research efforts are well published in peer reviewed journals, including the Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, and Pharmacotherapy.
Relevant Financial Relationship Disclosure
No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company.
As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant financial relationships have been mitigated prior to the CPE activity.
Ryan Sullivan, M.D.
Associate Director, Melanoma Program
Massachusetts General Hospital Cancer Center
Associate Professor
Harvard Medical School
Boston, Massachusetts
Ryan Sullivan, M.D., is Attending Physician in the Division of Hematology/Oncology at Massachusetts General Hospital (MGH) in Boston, Massachusetts. He is board certified in Medical Oncology. At the MGH, Dr. Sullivan is Associate Director of the Melanoma Program and a member of the Termeer Center for Targeted Therapies. He is also Associate Professor of Medicine at Harvard Medical School. Dr. Sullivan is an active clinical and translational investigator. He has an interest in improving the prediction, through the development of blood-based biomarkers, and management of immune checkpoint inhibitor toxicity. Finally, he is a member of several national organizations including the American Society of Clinical Oncology, the American Association for Cancer Research, and the Society for the Immunotherapy of Cancer (SITC), and he serves as the Chair of the SITC Immunotherapy Resistance Committee Leadership Taskforce.
Relevant Financial Relationship Disclosure
Merck: research grants, consultant
BMS: consultant
All other persons in control of content do not have any relevant financial relationships with an ineligible company.
As defined by the Standards of Integrity and Independence definition of ineligible company. All relevant financial relationships have been mitigated prior to the CE activity